How It Works
- History
- How It Works
- FAQ
- Values
- ESG Commitment
- Definitions

Portfolio
Latest Articles

PANCREATIC CANCER

OncoSil™ receives CE Mark approval

OncoSil granted FDA Breakthrough Device Designation

March 18th 2020

OncoSil granted FDA Breakthrough Device Designation

Connect with us

EXPLORE

Finfeed Portfolio

Latest Articles

Archived Articles

About StocksDigital

PORTFOLIOS

Catalyst Hunter

STOCKS

FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS

CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY

The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).

© 2021 | AFSL (CAR No.433913)